H.R. 9169: PKD Cures Act

This legislation, known as the PKD Cures Act, aims to enhance research and innovation focused on polycystic kidney disease (PKD), a common genetic disorder affecting hundreds of thousands of Americans. The bill outlines several key provisions to support this objective.

Background and Findings

The bill starts by acknowledging that:

• PKD is a serious genetic disease that affects approximately 500,000 Americans and many more worldwide.
• The disease can lead to kidney failure, necessitating treatments such as dialysis or transplantation.
• A significant percentage of patients in the Medicare End-Stage Renal Disease program suffer from kidney failure due to PKD.
• Medicare incurs around $3 billion annually in costs related to kidney failure caused by cystic kidney diseases, primarily PKD.

Research Expansion

The bill mandates an expansion of research activities related to PKD through the National Institutes of Health (NIH). Specifically, the Director of the NIH is instructed to:

• Intensify research efforts to understand the genetic and molecular causes of PKD.
• Advance translational research to find biomarkers and therapeutic targets for PKD treatment.
• Conduct clinical research to assess the safety and effectiveness of both new and existing treatments.

Collaboration with federal agencies, academic institutions, and private sector stakeholders is emphasized to speed up the development of PKD treatments. The Director will also support training programs for future researchers and clinicians in the field of PKD.

Research Prioritization

In prioritizing research proposals, the Director of the NIH is directed to focus on those that have the greatest potential to improve understanding and treatment of PKD.

Development of a PKD Roadmap

The bill calls for the establishment of a working group tasked with creating a comprehensive roadmap for PKD research and innovation. Responsibilities of this group include:

• Identifying gaps in current research and determining priority areas.
• Recommending ways to improve collaboration between public and private entities.
• Setting timelines and benchmarks for achieving important milestones in PKD-related innovation.
• Formulating a strategy for incorporating new technologies, like artificial intelligence and precision medicine, into PKD research and care.

The working group will consist of experts in relevant fields, representatives from PKD advocacy organizations, and other stakeholders. A report detailing the findings and recommendations will be submitted to Congress within 24 months of the bill's enactment.

Relevant Companies

• NVS - Novartis AG: As a company involved in nephrology and pharmaceuticals, it may be affected by new research opportunities and potential treatments arising from the bill.
• FPRX - Fortis Therapeutics: This firm works on therapies for kidney diseases and may benefit from increased research funding for PKD.